Introduction about Global infectious disease and use of nanotechnology

Authors

  • Ankita Y. Gawai Department of Pharmaceutics, Shri Swami Samarth Institute of Pharmacy, At. Parsodi, Dhamangaon Rly, Dist. Amravati (444709) Maharashtra, India
  • Ravindra L. Bakal Department of Pharmaceutics, Shri Swami Samarth Institute of Pharmacy, At. Parsodi, Dhamangaon Rly, Dist. Amravati (444709) Maharashtra, India https://orcid.org/0000-0002-4964-4654
  • Pooja Ramdas Hatwar Department of Pharmaceutics, Shri Swami Samarth Institute of Pharmacy, At. Parsodi, Dhamangaon Rly, Dist. Amravati (444709) Maharashtra, India https://orcid.org/0000-0002-5424-3425
  • Krushnali N. Nehar Department of Pharmaceutics, Shri Swami Samarth Institute of Pharmacy, At. Parsodi, Dhamangaon Rly, Dist. Amravati (444709) Maharashtra, India
  • Pranali R. Bhujade Department of Pharmaceutics, Shri Swami Samarth Institute of Pharmacy, At. Parsodi, Dhamangaon Rly, Dist. Amravati (444709) Maharashtra, India

Abstract

Infectious diseases, including COVID-19, malaria, tuberculosis, and sexually transmitted diseases (STDs), pose significant threats to global health. Nanotechnology has emerged as a promising tool in the diagnosis, treatment, and prevention of these diseases. This review highlights the applications of nanotechnology in combating infectious diseases. Nanoparticles, such as metallic nanoparticles, liposomes, and quantum dots, have been employed in the detection and treatment of infectious diseases. Nanotechnology-based drug delivery systems have improved the efficacy and reduced the toxicity of antiviral and antibacterial drugs. Additionally, nanotechnology has enabled the development of point-of-care diagnostics and vaccines for infectious diseases. This review provides an overview of the current state of nanotechnology in infectious disease management and highlights its potential to revolutionize the field. By leveraging the unique properties of nanoparticles, nanotechnology can provide innovative solutions for the diagnosis, treatment, and prevention of infectious diseases, ultimately improving global health outcomes.

Keywords: Nanotechnology, Infectious diseases, COVID-19, Malaria, Tuberculosis, HIV/AIDS

Keywords:

Nanotechnology, , Infectious diseases, , COVID-19, Malaria,, Tuberculosis, HIV/AIDS

DOI

https://doi.org/10.22270/jddt.v14i12.6915

Author Biographies

Ankita Y. Gawai, Department of Pharmaceutics, Shri Swami Samarth Institute of Pharmacy, At. Parsodi, Dhamangaon Rly, Dist. Amravati (444709) Maharashtra, India

Department of Pharmaceutics, Shri Swami Samarth Institute of Pharmacy, At. Parsodi, Dhamangaon Rly, Dist. Amravati (444709) Maharashtra, India

Ravindra L. Bakal , Department of Pharmaceutics, Shri Swami Samarth Institute of Pharmacy, At. Parsodi, Dhamangaon Rly, Dist. Amravati (444709) Maharashtra, India

Department of Pharmaceutics, Shri Swami Samarth Institute of Pharmacy, At. Parsodi, Dhamangaon Rly, Dist. Amravati (444709) Maharashtra, India

Pooja Ramdas Hatwar , Department of Pharmaceutics, Shri Swami Samarth Institute of Pharmacy, At. Parsodi, Dhamangaon Rly, Dist. Amravati (444709) Maharashtra, India

Department of Pharmaceutics, Shri Swami Samarth Institute of Pharmacy, At. Parsodi, Dhamangaon Rly, Dist. Amravati (444709) Maharashtra, India

Krushnali N. Nehar, Department of Pharmaceutics, Shri Swami Samarth Institute of Pharmacy, At. Parsodi, Dhamangaon Rly, Dist. Amravati (444709) Maharashtra, India

Department of Pharmaceutics, Shri Swami Samarth Institute of Pharmacy, At. Parsodi, Dhamangaon Rly, Dist. Amravati (444709) Maharashtra, India

Pranali R. Bhujade, Department of Pharmaceutics, Shri Swami Samarth Institute of Pharmacy, At. Parsodi, Dhamangaon Rly, Dist. Amravati (444709) Maharashtra, India

Department of Pharmaceutics, Shri Swami Samarth Institute of Pharmacy, At. Parsodi, Dhamangaon Rly, Dist. Amravati (444709) Maharashtra, India

References

1) Al-Awsi GRL, Alameri AA, Al-Dhalimy AMB, Gabr GA, Kianfar E. Application of nano-antibiotics in the diagnosis and treatment of infectious diseases. Braz J Biol. 2023 Jan 30;84:e264946. PMID: 36722677. https://doi.org/10.1590/1519-6984.264946

2) Hauck TS, Giri S, Gao Y, Chan WC. Nanotechnology diagnostics for infectious diseases prevalent in developing countries. Adv Drug Deliv Rev. 2010 Mar 18;62(4-5):438-48. PMID: 19931580. https://doi.org/10.1016/j.addr.2009.11.015

3) Alabdali A Y M, Kzar M, Chinnappan S, Mani R R, Xin C K, Ting I T Y, Yung L J, Wei P L Y. Nanotechnology in the Treatment of Infectious Diseases: A Review. International Journal of Nanoscience and Nanotechnology, 2023; 19(1): 1-8. doi: 10.22034/ijnn.2023.531029.2056

4) Omietimi HB, Afolalu SA, Kayode JF, Monye SI, Lawal SL, Emetere ME, "An overview of nanotechnology and its application'' E3S Web of Conferences, 2023;391:01079. https://doi.org/10.1051/e3sconf/202339101079

5) Chintagunta AD, Sai krishna M, Nalluru S, "Nanotechnology: an emerging approach to combat COVID-19" emergent mater,2021;4:119-130. https://doi.org/10.1007/s42247-021-00178-6 PMid:33615141 PMCid:PMC7883336

6) Srujana S, Anjamma M, Alimuddin, Singh B, Dhakar RC, Natarajan S, Hechhu R. A Comprehensive Study on the Synthesis and Characterization of TiO2 Nanoparticles Using Aloe vera Plant Extract and Their Photocatalytic Activity against MB Dye. Adsorption Science & Technology. 2022;2022 https://doi.org/10.1155/2022/7244006

7) Balkrishna A, Arya V, Rohela A, Kumar A, Verma R, Kumar D, Nepovimova E, Kuca K, Thakur N, Thakur N and Kumar P, "Nanotechnology Interventions in the Management of COVID-19: Prevention, Diagnosis and Virus-Like Particle Vaccines'' Vaccines 2021;9:1129. https://doi.org/10.3390/vaccines9101129 PMid:34696237 PMCid:PMC8537718

8) Araste, F., Bakker, A.D. & Zandieh-Doulabi, B. Potential and risks of nanotechnology applications in COVID-19-related strategies for pandemic control. J Nanopart Res 2023;25:229. https://doi.org/10.1007/s11051-023-05867-3

9) Bagmar N A, Hatwar P R. and Bakal Dr. R. L, "A Review On Targeted Drug Delivery System, World Journal of Pharmaceutical Research,2023;12(19):288-298. DOI:10.20959/wjpr202319-30070

10) Gupta AK, Singh A, Singh S, "Diagnosis of Tuberculosis: Nanodiagnostics Approaches" NanoBioMedicine, 2021;261-283. https://doi.org/10.1007/978-981-32-9898-9_11

11) Pradhan D, Biswasroy P, Goyal A, Ghosh G, and Rath G, "Recent Advancement in Nanotechnology-Based Drug Delivery System Against Viral Infections" pharmaceutical science and technology,2021;22(47):2-19. https://doi.org/10.1208/s12249-020-01908-5 PMid:33447909 PMCid:PMC7808403

12) Bismillah M, Aunza N A, Rasool R, Ullah I, Syed S I, Alshehri S, Ghoneim Mohd M, Alzarea S I, Nadeem Mohd S, Kazmi I, "Nanotechnology as a Novel Approach in Combating Microbes Providing an Alternative to Antibiotics'' Antibiotics, 2021;10 (1473): 2-61. https://doi.org/10.3390/antibiotics10121473 PMid:34943685 PMCid:PMC8698349

13) Chaves JB, Portugal Tavares de Moraes B, Regina Ferrarini S, Noé da Fonseca F, Silva AR and Gonçalves-de-Albuquerque CF, "Potential of nano formulations in malaria treatment'' Frontiers in Pharmacology,2022; 13:999300. https://doi.org/10.3389/fphar.2022.999300 PMid:36386185 PMCid:PMC9645116

14) Ayan S, Aranci-Ciftci K, Ciftci F and Ustundag CB, "Nanotechnology and COVID-19: Prevention, diagnosis, vaccine, and treatment strategies", Frontiers in Materials,2023; 9:1059184. https://doi.org/10.3389/fmats.2022.1059184

15) Mehta OP, Bhandari P, Raut A, Kacimi SEO and Huy NT, "Coronavirus Disease (COVID-19): Comprehensive Review of Clinical Presentation", Frontiers in Public Health,2021; 8:582932. https://doi.org/10.3389/fpubh.2020.582932 PMid:33520910 PMCid:PMC7844320

16) Estefânia V. R. Campos, Anderson E. S. Pereira, Oliveira JLD, Carvalho LB, Guilger Casagrande M , Lima RD and Fraceto LF, "How can nanotechnology help to combat COVID-19? Opportunities and urgent need", Journal of Nanobiotechnology, 2020;18(125):2-23. https://doi.org/10.1186/s12951-020-00685-4 PMid:32891146 PMCid:PMC7474329

17) Mollarasouli F, Zare Shehneh N, Ghaedi M, "A review on corona virus disease 2019 (COVID 19): current progress, clinical features and bioanalytical diagnostic methods", Microchimica Acta, 2022;189(103):2-25. https://doi.org/10.1007/s00604-022-05167-y PMid:35157153 PMCid:PMC8852957

18) Alimardani V, Abolmaali SS, and Tamaddon A Mohd, "Recent Advances on Nanotechnology-Based Strategies for Prevention, Diagnosis, and Treatment of Coronavirus Infections", Jounral of Nanomaterial, 2021;1-20. https://doi.org/10.1155/2021/9495126

19) Ong CWM, Migliori GM, Raviglione M, MacGregor-Skinner G, Sotgiu G, Alffenaar JW, Tiberi S, Adlhoch C, Alonzi T, Archuleta S, Brusin S, Cambau E, Capobianchi MR, Castilletti C, Centis R, Cirillo DM, Ambrosio LD, Delogu G, Esposito SMR, Figueroa J, Friedland JS, Ho BCH, Ippolito G, Jankovic M, Kim HY, Klintz SR, Ködmön C, Lalle E, Leo YS, Leung CC, Märtson AG, Melazzini MG, Fard SN, Penttinen P, Petrone L, Petruccioli E, Pontali E, Saderi L, Santin M, Spanevello A, Crevel AV, Werf MJVD, Visca D, Viveiros M, Zellweger JP, Zumla A and Goletti D, "Epidemic and pandemic viral infections: impact on tuberculosis and the lung'', European Respiratory Journal,2020;56(2001727) https://doi.org/10.1183/13993003.01727-2020 PMid:32586885 PMCid:PMC7527651

20) Huang X, Kon E, Han E, Zhang X, Kong N, Mitchell M J, Peer D, and Tao W, "Nanotechnology-based strategies against SARS-CoV-2 variants" Nature Nanotechnology, 2022;17(10):1027-1037. https://doi.org/10.1038/s41565-022-01174-5 PMid:35982317

21) Rai M, Bondea S, Yadava A, Plekhanovac Y, Reshetilovc A, Guptad I, P Golińskab, R Pandita and Ingle A P, "Nanotechnology-based promising strategies for the management of COVID-19: current development and constraints'', Expert Review Of Anti-Infective Therapy,2022;20(10):1299-1308. https://doi.org/10.1080/14787210.2021.1836961 PMid:33164589

22) Yayehrad AT, Siraj EA, Wondie GB, Alemie AA, Derseh MT, Ambaye AS, "Could Nanotechnology Help to End the Fight Against COVID-19? Review of Current Findings, Challenges and Future Perspectives" Int J Nanomedicine, 2021;16:5713-5743. https://doi.org/10.2147/IJN.S327334 PMid:34465991 PMCid:PMC8402990

23) Vazquez-Munoz R, Lopez-Ribot JL, "Nanotechnology as an Alternative to Reduce the Spread of COVID-19'', Challenges, 2020;11(15):2-14. https://doi.org/10.3390/challe11020015

24) Souri M, Chiani M, Farhangi A, Mehrabi MR, Nourouzian D, Raahemifar K, Soltani M, "Anti-COVID-19 Nanomaterials: Directions to Improve Prevention, Diagnosis, and Treatment" Nanomaterials 2022;12(5):7832-40. https://doi.org/10.3390/nano12050783 PMid:35269270 PMCid:PMC8912597

25) Tavakol S, Zahmatkeshan M, Mohammadinejad R, Mehrzadi S, Joghataei MT, Alavijeh MS, Seifalian A, "The role of nanotechnology in current COVID-19 outbreak'' Heliyon, 2021;4(7):e06841. https://doi.org/10.1016/j.heliyon.2021.e06841 PMid:33880422 PMCid:PMC8049405

26) Majumder J, Minko T, "Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19", The AAPS Journal,2021;23(1):1-22. https://doi.org/10.1208/s12248-020-00532-2 PMid:33400058 PMCid:PMC7784226

27) Singh P, Singh D, Sa P, Mohapatra P, Khuntia A, K Sahoo S, "Insights from nanotechnology in COVID-19: prevention, detection, therapy and immunomodulation" Nanomedicine (Lond). 2021 J;16(14):1219-1235. https://doi.org/10.2217/nnm-2021-0004 PMid:33998837 PMCid:PMC8127834

28) Cavalcanti IDL, Cajubá de Britto Lira Nogueira M, "Pharmaceutical nanotechnology: which products are been designed against COVID-19?" J Nanopart Res 22, 276 (2020). https://doi.org/10.1007/s11051-020-05010-6 PMid:32922162 PMCid:PMC7480001

29) Andrade M V, Noronha K, Diniz B P C, Guedes G, Carvalho L R, Silva V A, Calazans J A, Santos A S, Silva D N and Castro M C, "The economic burden of malaria: a systematic review'' Malaria Journal,2022;21(283):1-10. https://doi.org/10.1186/s12936-022-04303-6 PMid:36199078 PMCid:PMC9533489

30) Varo R, Chaccour C, Bassat Q, "Update on malaria", Med Clin (Barc), 2020;155(9):395-402. https://doi.org/10.1016/j.medcli.2020.05.010 PMid:32620355

31) Nureye D and Assefa S, "Old and Recent Advances in Life Cycle, Pathogenesis, Diagnosis, Prevention, and Treatment of Malaria Including Perspectives in Ethiopia'', Scientific World Journal,2020;115. https://doi.org/10.1155/2020/1295381

32) Possemiers H, Leen Vandermosten ID, Philippe E. Van den SteenI D, "Etiology of lactic acidosis in malaria" PLOS PATHOGENS,2021;17(1):1-17. https://doi.org/10.1371/journal.ppat.1009122 PMid:33411818 PMCid:PMC7790250

33) Trivedi S, Chakravarty A, "Neurological Complications of Malaria", Current Neurology and Neuroscience Reports,2022;22:499-513. https://doi.org/10.1007/s11910-022-01214-6 PMid:35699901 PMCid:PMC9192935

34) Gujjari L, Kalani H, Pindiprolu SK, Arakareddy B P, Yadagiri G, '' Current challenges and nanotechnology-based pharmaceutical strategies for the treatment and control of malaria", Parasite Epidemiology and Control,2022;17:e00244. https://doi.org/10.1016/j.parepi.2022.e00244 PMid:35243049 PMCid:PMC8866151

35) Hassan AO, Oso OV, Obeagu EI and Adeyemo AT, "Malaria Vaccine: Prospects And Challenges" Madonna University Journal of Medicine and Health Sciences,2022;2(2):22-40.DIO:https://orcid.org/0000-0002-4538-0161

36) Saftawy E EL, Farag MF, Gebreil HH, Abdelfatah M, Aboulhoda BE, Alghamdi M, Albadawi EA, Abd Elkhalek MA, "Malaria: biochemical, physiological, diagnostic, and therapeutic updates" PeerJ,2024;12(e17084):1-21. https://doi.org/10.7717/peerj.17084 PMid:38529311 PMCid:PMC10962339

37) Acharya B, Acharya A, Gautam S, Ghimire S P, Mishra G, Parajuli N, Sapkota B, "Advances in diagnosis of Tuberculosis: an update into molecular diagnosis of Mycobacterium tuberculosis", Molecular Biology Reports, 2020;47:4065-4075. https://doi.org/10.1007/s11033-020-05413-7 PMid:32248381

38) McQuaid CF, McCreesh N, Read JM, Sumner T; CMMID COVID-19 Working Group; Houben RMGJ, White RG, Harris RC, "The potential impact of COVID-19-related disruption on tuberculosis burden" Eur Respir J. 2020;56(2):2001718. https://doi.org/10.1183/13993003.01718-2020 PMid:32513784 PMCid:PMC7278504

39) Natarajan A, Beena P M, Devnikar A V, Mali S, '' A systemic review on tuberculosis'' Indian Journal of Tuberculosis, 2020;(67):295-311. https://doi.org/10.1016/j.ijtb.2020.02.005 PMid:32825856

40) Obeagu EI and Obeagu GU, " Human Immunodeficiency Virus and tuberculosis infection: A review of prevalence of associated factors'' International Journal of Advanced Multidisciplinary Research, 2023;10(10):56-62. http://dx.doi.org/10.22192/ijamr.2023.10.10.005

41) Panic N, Maetzel H, Bulajic M, Radovanovic M, and J-Matthias Lohr, "Pancreatic tuberculosis: A systematic review of symptoms, diagnosis and treatment'', United European Gastroenterology Journal, 2020;8(4):396-402. https://doi.org/10.1177/2050640620902353 PMid:32213022 PMCid:PMC7226685

42) Kaur M, Gogna S, Reetika, Kaur N, Minhas P, Sharma D, Katual M K, "Nano-Technological Developments in Tuberculosis Management: An Update'', Tathapi UGC Care Journal, 2020;19(5):313-329.

43) Gupta M, Shivangi, Laxman S. Meena, "Multidirectional Benefits of Nanotechnology in the Diagnosis, Treatment and Prevention of Tuberculosis'', Journal of Nanotechnology and Nanomaterials, 2020;1(2):46-56.DIO: https://www.scientificarchives.com/journal/journal-of-nanotechnology-and-nanomaterials https://doi.org/10.33696/Nanotechnol.1.008

44) Cheepsattayakorn A and Cheepsattayakorn R, "Roles of Nanotechnology in Diagnosis and Treatment of Tuberculosis", Journal of Nanotechnology in Diagnosis and Treatment, 2013;1(1):19-25. https://doi.org/10.12974/2311-8792.2013.01.01.3

45) Chen W, Huang L, Tang Q, Wang S, Hu C, Zhang X, "Progress on diagnosis and treatment of central nervous system tuberculosis" Radiology of Infectious Diseases, 2020;7(4):160-169. https://doi.org/10.1016/j.jrid.2020.07.005

46) Ahmad F, Pandey N, Singh K, Ahmad S, Khubaib M, Sharma R, "Recent Advances in Nanocarrier-Based Therapeutic and Diagnostic Approaches in Tuberculosis" Precis. Nanomed, 2023;6(4). 1134-1156. https://doi.org/10.33218/001c.90699

47) Van Gerwen OT, Muzny CA and Marrazzo JM, "Sexually transmitted infections and female reproductive health" Nature Microbiology, 2022;7:1116-1126. https://doi.org/10.1038/s41564-022-01177-x PMid:35918418 PMCid:PMC9362696

48) Adamson PC, Loeffelholz MJ, Klausner JD, "Point-of-Care Testing for Sexually Transmitted Infections: A Review of Recent Developments", Arch Pathol Lab Med, 2020;144(11):1344-1351. doi: 10.5858/arpa.2020-0118-RA. https://doi.org/10.5858/arpa.2020-0118-RA PMid:32810868 PMCid:PMC7606737

49) Homes KK, Levine R, Weaver M, "Effectiveness of condoms in preventing sexually transmitted infection, Public Health Review", Bulletin of the World Health Organization, 2004;82(6):454-461.

50) Sahoo CK, Sahoo NK, Rao SRM, Sudhakar M, "A Review on Prevention and Treatment of Aids", Pharmacy & Pharmacology International Journal, 2017; 5(1): 00108. https://doi.org/10.15406/ppij.2017.05.00108

51) O'Byrne P, MacPherson P, Orser L, "Approach to sexually transmitted infection testing for men who have sex with men" Can Fam Physician, 2024;70(7-8):449-455. https://doi.org/10.46747/cfp.700708449 PMid:39122439 PMCid:PMC11328724

52) Stump DS and Woude SV, "Animal Models for HIV AIDS: A Comparative Review" Comparative Medicine Copyright 2007 by the American Association for Laboratory Animal Science, 2007;57:33-43,

53) Zhou J, Krishnan N, Jiang Y, FangR H, Zhang L, "Nanotechnology for virus treatment" Nano Today, 2021;36: 101031. https://doi.org/10.1016/j.nantod.2020.101031 PMid:33519948 PMCid:PMC7836394

Published

15-12-2024
Statistics
Abstract Display: 183
PDF Downloads: 98
PDF Downloads: 13

How to Cite

1.
Gawai AY, Bakal RL, Hatwar PR, Nehar KN, Bhujade PR. Introduction about Global infectious disease and use of nanotechnology. J. Drug Delivery Ther. [Internet]. 2024 Dec. 15 [cited 2025 May 16];14(12):181-90. Available from: https://www.jddtonline.info/index.php/jddt/article/view/6915

Issue

Vol. 14 No. 12 (2024): Volume 14, Issue 12, December 2024

Section

Review

Copyright (c) 2024 Ankita Y. Gawai, Ravindra L. Bakal , Pooja Ramdas Hatwar , Krushnali N. Nehar, Pranali R. Bhujade

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).

How to Cite

1.
Gawai AY, Bakal RL, Hatwar PR, Nehar KN, Bhujade PR. Introduction about Global infectious disease and use of nanotechnology. J. Drug Delivery Ther. [Internet]. 2024 Dec. 15 [cited 2025 May 16];14(12):181-90. Available from: https://www.jddtonline.info/index.php/jddt/article/view/6915
Crossref
Scopus
Google Scholar
Europe PMC

Most read articles by the same author(s)